Navigation Links
Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
Date:12/6/2007

RICHMOND, Va., Dec. 6 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced today that it will present at the IBC 5th Annual Global Follow-On Biologics Conference on December 11, 2007 at 09:15 AM Eastern Time.

The conference, to be held at the Hyatt Regency Hotel in Reston, Virginia, will run from Monday, December 10th through Tuesday, December 11th, and will bring together corporate, regulatory, financial, and legal experts in the field of follow-on biologics. Geoffrey Allan, Ph.D., Insmed President and CEO, will discuss Insmed's comprehensive portfolio of follow-on biologics. His presentation, entitled, "The Development of a Broad Portfolio of Follow-On Biologics: Clinical/Regulatory/Analytical and Commercial Challenges and Strategies," will also highlight Insmed's strategy for providing patients greater choice through access to these innovative follow-on biologics.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. AtriCure to Present at Roth Capital Partners 2007 New York Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. MDS to Present at Thomas Weisel Partners Healthcare Conference
9. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
10. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Pigment Laser Tattoo Removal Center is proud ... the new PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. ... picosecond laser on the market. Jeremy Miller, Tattoo Artist and former reality show ...
(Date:5/5/2016)... ... 2016 , ... Linfield College Online and Continuing Education is encouraging registered nurses ... application fee for all qualified applicants from May 1–14. Students need only go to ... applying . , With the RN to BSN degree program, all ...
(Date:5/5/2016)... ... ... Is the part in your hair widening? Are you finding more hairs ... good opportunity to raise awareness about a common condition among women: hair loss. , ... experience hair loss or ‘thinning’ by the time they reach menopause, but many remain ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Dr. Julie Lombardo, PT, DPT, MA, OCS, WCS, has been selected by the ... Practice Award. The WPTA Private Practice Award is awarded annually to a member ...
(Date:5/4/2016)... PA (PRWEB) , ... May 04, 2016 , ... Mother ... that grow – flowers, plants, fruits and vegetables. , Celebrate these women with ... your life, an unexpected gift with these five garden-themed options. , Vibrant, Edible, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Calif. , May 3, 2016  While you may be familiar with watching a film ... , also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned ... of innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
(Date:5/3/2016)... JERUSALEM , May 3, 2016 ... (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the ... Clinical and Regulatory Affairs. "Ms. Strauss-Levy has ... affairs, and has established an outstanding track record, having ... development and regulatory approval processes in the ...
Breaking Medicine Technology: